They act by reducing GH production and induce tumor size shrinkage by binding to somatostatin receptors (SSTRs) on the pituitary tumor, with SSTR2 and the SSTR5 being the most prevalent and studied receptor types [5]. Here, GH1 is linked to neoplasm.